Wormwood

Metadata

• Common Names: Wormwood, Absinth Wormwood (English); Wermutkraut (German)
• Botanical Name: Artemisia absinthium L.
• Plant Family: Asteraceae (Compositae)
• Part Used: Aerial parts / Herb (Absinthii herba)
• Evidence Quality Rating: Preliminary (strong traditional evidence and pharmacological rationale; very limited clinical trial data)

Approved Indications

Commission E

• Loss of appetite
• Dyspeptic complaints
• Biliary dyskinesia (impaired bile flow)

ESCOP

• Loss of appetite (anorexia)
• Digestive disorders
• Short-term use recommended (3-4 weeks maximum)

EMA/HMPC

• Well-established use: Temporary loss of appetite (based on long-standing use and pharmacological plausibility of bitter-mediated appetite stimulation)
• Traditional use: Mild dyspeptic/gastrointestinal complaints such as mild heartburn and stomach/gut disorders
• Notably, the EMA granted “well-established use” for the appetite indication — this is stronger than many other bitter herbs received

Agreement/Disagreement Between Bodies

• All three bodies agree on loss of appetite and dyspeptic complaints
• Commission E uniquely includes biliary dyskinesia
• The EMA distinguishes between well-established use (loss of appetite) and traditional use (dyspepsia) — an important regulatory nuance
• ESCOP specifically limits duration to 3-4 weeks
• All bodies emphasize short-term use only due to thujone content

Conditions Treated

• Loss of appetite / Anorexia (non-psychiatric, e.g., convalescence)
• Functional dyspepsia
• Bloating / Flatulence
• Biliary dyskinesia
• Mild heartburn
• Mild gastric complaints

Mechanism of Action

• Bitter compounds: Wormwood is extremely bitter; the bitterness value (Bitterwert) ranges from 10,000-25,000
  • Absinthin and artabsin (sesquiterpene lactones): Principal bitter principles; stimulate gustatory nerves, triggering reflex secretion of saliva, gastric juice, and bile via vagal pathways
  • Anabsinthin: Contributing bitter compound
• Bitter taste receptor activation: Activates TAS2R bitter taste receptors on the tongue and in gastrointestinal enteroendocrine cells
• Choleretic activity: Stimulates bile production and flow
• Anti-inflammatory: Sesquiterpene lactones and flavonoids inhibit NF-kB and pro-inflammatory cytokines
• Antimicrobial: Essential oil components (thujone, chamazulene) show broad-spectrum antimicrobial activity
• Thujone (alpha- and beta-thujone): Primary component of essential oil; GABA-A receptor antagonist — responsible for neurotoxic effects at high doses; at very low doses, may contribute to the overall pharmacological profile
• Antiparasitic: Traditional use for intestinal parasites (hence the name “wormwood”); some in vitro evidence supports anthelmintic activity

Clinical Evidence Summary

• Very limited RCT data for digestive indications specifically
• Crohn’s Disease trial: Omer et al. (2007) — small RCT (n=40) showed wormwood extract (3x500mg/day) allowed steroid tapering in Crohn’s disease patients with significant clinical improvement (CDAI reduction) and improved quality of life vs placebo. This study generated interest but has not been replicated [NEEDS-RESEARCH]
• Pharmacological basis: The mechanism of bitter-taste-mediated digestive stimulation is well-established physiologically; the EMA considered this sufficient to justify well-established use status for appetite stimulation
• Traditional documentation: Extensive historical use documentation across European pharmacopoeias for at least several centuries
• No large-scale clinical trials for dyspepsia or appetite loss indications per se
• The gap between strong traditional/pharmacological evidence and absent modern RCT evidence is notable

European vs US/Anglophone Consensus

• Wormwood is a classical European bitter medicine; the tradition of Wermut (vermouth) derives directly from this herb
• In Germany, wormwood preparations are available in pharmacies as standardized bitter tonics
• In the US, wormwood is classified as unsafe by the FDA due to thujone content; it is not permitted in food unless thujone-free
• This creates a stark regulatory divergence: The EMA grants well-established use status while the FDA considers it potentially unsafe
• The US concern is driven primarily by the historical association with absinthe and thujone neurotoxicity, while European regulators have concluded that at therapeutic doses (with defined thujone limits), the benefits outweigh the risks
• US practitioners who use wormwood typically do so in naturopathic or traditional herbal medicine contexts, outside mainstream medicine

Safety Profile

Contraindications

• Pregnancy: Absolutely contraindicated — classified as an abortifacient; high thujone content poses fetal toxicity risk
• Breastfeeding: Contraindicated
• Epilepsy and seizure disorders: Thujone is a GABA-A antagonist and can lower seizure threshold
• Gastric/duodenal ulcer: Bitter stimulation of gastric acid may exacerbate ulcers
• Hyperacidity / Acid reflux
• Known allergy to Asteraceae/Compositae family

Drug Interactions

• Anticonvulsant medications: Wormwood may reduce effectiveness of phenobarbital, valproic acid (Depakene), primidone (Mysoline), gabapentin (Neurontin), carbamazepine (Tegretol), phenytoin (Dilantin) by antagonizing GABA-mediated inhibition
• Warfarin and anticoagulants: Theoretical interaction (insufficient data)
• Disulfiram/metronidazole: Alcohol-based tinctures may interact

Side Effects

• At recommended doses: generally well tolerated for short-term use
• Nausea, vomiting (especially at higher doses)
• Dizziness, headache
• Thujone toxicity (overdose/long-term use): Seizures, convulsions, delirium, stupor, urine retention, severe diarrhea, intestinal cramps
• Restlessness, insomnia (from CNS stimulation)
• Allergic reactions (rare, Compositae cross-sensitivity)

Thujone Limits

• Medicinal preparations must contain less than 6.0 mg thujone to avoid toxic quantities
• European Pharmacopoeia sets thujone limits for wormwood preparations
• Traditional absinthe (historical) contained much higher thujone levels than modern therapeutic preparations

Pregnancy/Lactation

• Absolutely contraindicated in pregnancy and lactation
• Thujone is a documented abortifacient
• Can significantly disrupt pregnancy

Clinical Dosage

Forms and Ranges

• Dried herb (tea): 2-3 g of herb per day in divided doses, as infusion, taken before meals
• Tincture (1:5 in 70% ethanol): 10-30 drops, 30 minutes before meals, 2-3 times daily
• Pressed juice: 5-10 mL fresh herb juice daily
• Maximum duration: 3-4 weeks (ESCOP); do not exceed 4 weeks continuous use
• Timing: Always before meals to maximize bitter-mediated appetite stimulation

Key Standardized Products

• Wermutkrauttinktur (wormwood tincture) — German pharmacy product
• Absinthii herba preparations per European Pharmacopoeia
• Component of traditional Swedish Bitters (Schwedenbitter) formulations
• Often found in combination bitter formulations with gentian

Sources

• EMA/HMPC European Union Herbal Monograph on Artemisia absinthium L., herba (Revision 1)
• EMA/HMPC Assessment Report on Artemisia absinthium L., herba
• Commission E Monograph: Absinthii herba
• ESCOP Monograph: Absinthii herba
• Omer B, et al. Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn’s disease. Phytomedicine. 2007;14:87-95
• Lachenmeier DW, et al. Absinthe — a review. Crit Rev Food Sci Nutr. 2006;46(5):365-377
• Bora KS, Sharma A. The genus Artemisia: a comprehensive review. Pharm Biol. 2011;49(1):101-109
• Arzneipflanzenlexikon: Wormwood (arzneipflanzenlexikon.info)

Connections

• Closely related to Gentian as fellow bitter digestive tonic; both work via TAS2R bitter receptor activation
• The thujone safety concern is unique among herbs in this collection; compare with Fennel estragole concerns for parallel regulatory toxicology issues
• The FDA vs EMA regulatory divergence on wormwood is one of the starkest examples in this herb collection
• Wormwood is a classical component of vermouth and absinthe, connecting phytotherapy to European cultural history